Novartis Q4 Results
Content
Click below to navigate
through the document
Novartis delivers strong full year performance with margin expansion.
Continuing innovation momentum with multiple positive Ph3 readouts
↓
↑
Company overview
Core margin
36.0% (+240 bps)
Core Oplnc
USD 16.4bn
Several major innovation milestones in Q4
FabhaltaⓇ (iptacopan) US approval in PNH
CosentyxⓇ US approval in HS
Cosentyx® US approval of IV formulation (PSA, AS, nr-axSpA)
Iptacopan Ph3 APPLAUSE study met its primary endpoint in IgAN
Atrasentan Ph3 ALIGN study met its primary endpoint in IgAN
Iptacopan Ph3 APPEAR-C3G met its primary endpoint in C3G
ScemblixⓇ Ph3 ASC4FIRST met primary endpoints in 1L Ph+ CML-CP (Jan)
Financial review
Conclusions
Appendix
References
Double-digit growth for sales and Core Oplnc
for the quarter and full year¹
Growth vs. PY, CC
Core margin
33.5% (+100 bps)
18%
13%
10%
10%
Sales
USD 11.4bn
Core Oplnc
USD 3.8bn
Sales
USD 45.4bn
Q4
FY
Successful spin-off
of Sandoz
FY 2024 guidance¹: Sales expected to grow mid single
digit; Core Oplnc expected to grow high single digit
Mid-term guidance¹ updated: Sales expected to grow +5% cc CAGR
2023-28; core operating income margin -40%+ by 2027
-
Oplnc operating income.
1. As defined on page 37 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate
activities Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
4View entire presentation